Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish |
---|
Total Ratings | 1 | 0 | 4 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 1 | 0 | 0 |
2M Ago | 1 | 0 | 2 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Editas Medicine, presenting an average target of $10.0, a high estimate of $15.00, and a low estimate of $7.00. This current average represents a 25.93% decrease from the previous average price target of $13.50.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light...
在過去的三個月中,有5位分析師對Editas Medicine(納斯達克股票代碼:EDIT)進行了評估,提供了從看漲到看跌的不同觀點。
下表彙總了他們最近的評級,闡明瞭過去30天內情緒的變化,並將其與前...